Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.

By J. Smerage, W. Barlow, G. Hortobagyi, E. Winer, B. Leyland-Jones, G. Srkalović, S. Tejwani, A. Schott, M. O'Rourke, D. Lew and 4 more. Journal of Clinical Oncology, 2014

604 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/ce9a828c8cab165fb8f26a4f246ad19ade3348bb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. C. Alix‐Panabières
2. K. Pantel

In Pulmonary and Respiratory Medicine

1. C. Alix‐Panabières
2. K. Pantel

Citations in the corpus

• Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments (2022, background): “CTC counts have also been reported to act as a better indicator of treatment response, with their reduced levels correlating with better overall survival (OS) in a large cohort of breast cancer (BC) patients [17].”
• Liquid Biopsy: From Discovery to Clinical Application. (2021, background): “One potential problem, however, might be that elevated CTC counts are indicators of worse prognosis, but the applied therapy may not change the course of the disease, as indicated by the results of the SWOG SO500 study (106).”